Brussels
Belgium
20
2015-12-24
The entities that hold a legal rights for patent applications filed by inventor VAN DER BRUGGEN Pierre:
Pierre VAN DER BRUGGEN from Brussels, BE has applied for patents for these inventions. The list has both pending applications and granted patents:
Melanoma-Associated MHC Class I Associated Oligopeptides and the Uses Thereof
#2 | 2011-04-12Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3
#3 | 2010-02-11Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients
#4 | 2010-01-14Isolated proteins MAGE-4 and MAGE-41
#5 | 2009-08-13MAGE-A3 PEPTIDES PRESENTED BY HLA-DR1 MOLECULES
#6 | 2009-04-23Melanoma-associated MHC class I associated oligopeptides and the uses thereof
#7 | 2008-06-17MAGE peptides presented by HLA class II molecules
#8 | 2008-04-01Tumor antigens and CTL clones isolated by a novel procedure
#9 | 2007-12-25MAGE-A4 antigenic peptides and uses thereof
#10 | 2007-08-07MAGE-3 peptides presented by HLA class II molecules
#11 | 2007-04-03Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof
#12 | 2007-01-02MAGE-A1 peptides presented by HLA class II molecules
#13 | 2006-09-21MAGE-A3 peptides presented by HLA class II molecules
#14 | 2006-06-15Isolated proteins MAGE-4 and MAGE-41
#15 | 2006-05-23MAGE-A3 peptides presented by HLA class II molecules
#16 | 2006-05-09Isolated peptides which bind to HLA-B18 molecules and uses thereof
#17 | 2005-11-10Isolated peptides which bind to HLA-A24 molecules and uses thereof
#18 | 2005-10-13Isolated peptide which binds to HLA-Cw*07 and uses thereof
#19 | 2005-09-20Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereof
#20 | 2005-09-06Isolated nucleic acid molecules which encode GAGE genes and uses thereof
1754057 ⎘